ProCE Banner Activity

SYMPHONY-1: Phase Ib Results of Tazemetostat + Lenalidomide and Rituximab in Relapsed/Refractory Follicular Lymphoma

Slideset Download
Conference Coverage

Tazemetostat combined with lenalidomide and rituximab for previously treated FL showed no unexpected safety signals and preliminary evidence of a high response rate.

Released: December 17, 2022

Expiration: December 16, 2023

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen